Site 108

Washington D.C., District of Columbia 20010

1 studies enrolling now · 1 studies all time

What they study most

Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) — Recruiting now